According to Table 2, in a CT of a liposome-based drug carrying the IFNB1 gene, patient survival was reported at 17 ± 4.5 months, with a more than 50% reduction in tumor size observed in 40% of patients (2 out of 5 cases) [169]. The gene discussed is IFNB1; the disease is neoplasm.